Insomnia and the Risk of Acute Myocardial Infarction A Population Study

Department of Public Health, Faculty of Medicine, Trondheim, Norway.
Circulation (Impact Factor: 14.43). 11/2011; 124(19):2073-81. DOI: 10.1161/CIRCULATIONAHA.111.025858
Source: PubMed


Few prospective studies have investigated insomnia in relation to risk for coronary heart disease. We assessed insomnia symptoms and risk of acute myocardial infarction (AMI) in a large, population-based study.
A total of 52 610 men and women were followed up for a first AMI, and 2368 incident AMIs occurred during 11.4 years of follow-up, either identified at hospitals or by the National Cause of Death Registry. In our analyses, we adjusted for age, sex, marital status, education, shift work, blood pressure, lipids, diabetes mellitus, body mass index, physical activity, smoking, and alcohol consumption. Difficulties initiating and maintaining sleep and having a feeling of nonrestorative sleep were associated with a moderate increase in AMI risk. The multiadjusted hazard ratios for AMI were 1.45 (95% confidence interval 1.18-1.80) for people with difficulties initiating sleep almost every night, 1.30 (1.01-1.68) for those with difficulties maintaining sleep almost every night, and 1.27 (1.03-1.57) for those with a feeling of nonrestorative sleep more than once a week compared with people who never experienced these sleep difficulties. When we combined the symptoms, a dose-dependent association was seen between the number of insomnia symptoms and AMI risk (P for trend 0.003). Alternative multivariable models and different sensitivity analyses suggest that the results were robust, especially concerning difficulties initiating sleep.
Insomnia is associated with a moderately increased risk for AMI.

Download full-text


Available from: Lars Erik Laugsand
  • Source
    • "It is also need of an hour to pay attention to sleep health in reducing global burden of NCDs [32]. Inadequate hours or disturbed sleep contribute to worsening atherosclerosis, hard cardiovascular endpoints, hypertension, diabetes and premature mortality3334353637. Partial sleep deprivation for one night (3.6 hours of sleep) in healthy subjects increases blood pressure and sympathetic activity compared with a night of normal sleep duration [39]. "

    Full-text · Article · Dec 2015
  • Source
    • "Among a total of 93,898 invited individuals, 65,215 (69%) provided information in a self-administered questionnaire, and attended a clinical examination that included blood sampling. Details about the study have been published elsewhere [25] [26]. Among the 65,215 participants, 5221 were excluded because they reported a history of MI, angina pectoris or stroke at baseline, and 1233 participants were excluded due to missing values on relevant covariates, leaving 58,761 participants eligible for analysis. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background and aims: CXCL16 is an interferon-γ-regulated chemokine and scavenger receptor for oxidized low-density lipoprotein that is expressed in atherosclerotic lesions. High soluble CXCL16 levels during acute cardiovascular events may indicate impaired long-term prognosis, but it is not known if CXCL16 is associated with the risk of developing cardiovascular disease in healthy individuals. We aimed to assess whether soluble CXCL16 is associated with risk of myocardial infarction (MI) in a nested case-control study within a large population-based cohort. Methods: We conducted a case-control study nested within the population-based HUNT2 cohort in Norway. A total of 58,761 men and women free of known cardiovascular disease were followed for a first myocardial infarction (MI), and during 11.3 years of follow-up, 1587 incident MIs were registered. These cases were compared to 3959 age- and sex-matched controls. Results: Among MI cases, the median CXCL16 concentration was 9.9 ng/ml (interquartile range 7.2-12.6) compared to 9.6 ng/ml (interquartile range 6.9-12.3) among controls (p < 0.001). Although the difference in median value between cases and controls was small, MI risk was twice as high (OR, 2.08; 95% CI: 1.74-2.50) among participants in the highest quartile compared to participants in the lowest quartile of CXCL16 after adjustment for age and sex. Additional adjustment for serum lipids, body mass index, smoking habits, diabetes mellitus, serum creatinine, and high-sensitivity C-reactive protein attenuated the excess risk by about half, yielding an odds ratio of 1.46 (95% CI: 1.19-1.79). Conclusion: Soluble CXCL16 may provide novel information in clinical cardiovascular risk assessment, but its importance needs to be verified in other prospective population studies.
    Full-text · Article · Nov 2015 · Atherosclerosis
  • Source
    • "Chronic insomnia has been associated with a number of negative health outcomes, including obesity and metabolic dysregulation [3] [4], hypertension and increased risk of myocardial infarction [5] [6], increased susceptibility to infections [7], and depression [8]. While pharmacotherapy remains the most commonly used treatment option, hypnotics such as benzodiazepine receptor agonists are associated with side-effects, dependence, and tolerance over time. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cognitive-behavioral therapy for insomnia (CBT-I) has been shown efficacious, but the challenge remains to make it available and accessible in order to meet population needs. Delivering CBT-I over the internet (eCBT-I) may be one method to overcome this challenge. The objective of this meta-analysis was to evaluate the efficacy of eCBT-I and the moderating influence of various study characteristics. Two researchers independently searched key electronic databases (1991 to June 2015), selected eligible publications, extracted data, and evaluated methodological quality. Eleven randomized controlled trials examining a total of 1460 participants were included. Results showed that eCBT-I improved insomnia severity, sleep efficiency, subjective sleep quality, wake after sleep onset, sleep onset latency, total sleep time, and number of nocturnal awakenings at post-treatment, with effect sizes (Hedges's g) ranging from 0.21 to 1.09. The effects were comparable to those found for face-to-face CBT-I, and were generally maintained at 4-48 wk follow-up. Moderator analyses showed that longer treatment duration and higher degree of personal clinical support were associated with larger effect sizes, and that larger study dropout in the intervention group was associated with smaller effect sizes. In conclusion, internet-delivered CBT-I appears efficacious and can be considered a viable option in the treatment of insomnia.
    Full-text · Article · Oct 2015 · Sleep Medicine Reviews
Show more